Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02236559 · ClinicalTrials.gov registry record · NA

High Flow Therapy for the Treatment of Respiratory Failure in the ED

A NA study of Acute Respiratory Failure, sponsored by Vapotherm.

Completed
Registry status
NA
Development phase
204
Enrollment target
5
Study locations

NCT02236559: Completed NA study of Acute Respiratory Failure, sponsored by Vapotherm.

NCT02236559 is a NA study of Acute Respiratory Failure that has completed, run by Vapotherm. The registered enrollment target is 204 participants, below the 1,466-participant average among 13 other Acute Respiratory Failure trials with a reported enrollment target (86% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02236559, a NA study of Acute Respiratory Failure, has completed, sponsored by Vapotherm.

COMPLETED
Registry status
NA
Development phase
204 participants
Enrollment target
5
Study locations

Study Summary

The overall objective of this study is to determine if Vapotherm high flow nasal cannula therapy (HFT), when used to treat respiratory failure in the ED, is at least equivalent to the current standard of care for non-invasive ventilatory support, non-invasive positive pressure mask ventilation (NIPPV). Moreover, this study will investigate the potential that HFT has possible advantages over NIPPV, such as decreased time to patient stability from respiratory failure, and the ease of use as a first line intervention for respiratory failure in the ED environment. The hypothesis is that HFT via the Vapotherm Precision Flow will demonstrate clinical non-inferiority when compared to NIPPV with regard to treatment failure by way of an impact on ventilation indices and a lower intolerance rate, and have a positive association with hospital disposition and length of stay.

Primary Outcome

Determine the efficacy of HFT compared to NIPPV in treating respiratory failure. The primary endpoint will be treatment failure within 72 hrs as determined by intubation.

Conditions Studied

Interventions

  • DEVICE Vapotherm
  • DEVICE Noninvasive positive pressure ventilation (NIPPV)

Study Locations (5)

Texas

  • Memorial Hermann Hospital - Houston
  • Memorial Hermann The Woodlands - The Woodlands

Georgia

  • Athens Regional Medical Center - Athens

South Carolina

  • McLeod Regional Medical Center - Florence

Tennessee

  • Erlanger Health System - Chattanooga

Trial Details

FieldValue
Enrollment Target 204 participants
Start Date 2014-09
Est. Completion 2017-02
Phase NA
Vapotherm

7 total trials

What the finished NCT02236559 record still lists

NCT02236559 is an interventional study that assigns participants to a tested intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap, below the 1,466-participant average among 13 other Acute Respiratory Failure trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Acute Respiratory Failure appearing as the primary indexed condition, and to 2 interventions - of which Vapotherm is the first listed.

NCT02236559 lists 5 locations in 4 states (Texas, Georgia, South Carolina).

Frequently Asked Questions

What is clinical trial NCT02236559 about?

NCT02236559 is a clinical study titled "High Flow Therapy for the Treatment of Respiratory Failure in the ED". The overall objective of this study is to determine if Vapotherm high flow nasal cannula therapy (HFT), when used to treat respiratory failure in the ED, is at least equivalent to the current standard of care for non-invasive ventilatory support, non-invasive positive pressure mask ventilation (NIPP...

What is the current status of trial NCT02236559?

This trial is currently completed. It is a NA study. The enrollment target is 204 participants. The study started on 2014-09. Estimated completion is 2017-02.

What conditions does trial NCT02236559 study?

This clinical trial studies the following conditions: Acute Respiratory Failure.

What interventions are being tested in trial NCT02236559?

The interventions under investigation include: Vapotherm (DEVICE), Noninvasive positive pressure ventilation (NIPPV) (DEVICE).

Who is sponsoring clinical trial NCT02236559?

This trial is sponsored by Vapotherm, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02236559 being conducted?

This trial has 5 study locations across Georgia, South Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Respiratory Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02236559's enrollment target sits among peer trials

204 8th of 13 higher than 6 of 13 other Acute Respiratory Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Respiratory Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03481010 · 204 participants · NA

    Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology

  • NCT04249830 · 204 participants · NA

    Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults

  • NCT04503395 · 204 participants · NA

    ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES

  • NCT04793776 · 204 participants · NA

    Manage Emotions to Reduce Aggression (MERA)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02236559, the US trial registry maintained by the National Library of Medicine. NCT02236559 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.